XML 80 R35.htm IDEA: XBRL DOCUMENT
v3.24.1

Summary of Significant Accounting Policies (Details) - V C N - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Oct. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 10, 2022
Summary of Significant Accounting Policies |  |  |  |  |
Additional consideration related to the achievement of certain milestones |  |  | $ 70,200,000 |  |
Amount to be paid due to approval |  | $ 3,000,000.0 |  |  |
Payment made after clinical trial | $ 3,250,000 |  |  |  |
Fair value of contingent consideration |  | $ 10,200,000 | 6,300,000 | $ 10,200,000 | $ 11,093,000
Fair value measurement, transfer in to level3 |  |  | 0 | $ 0 |
Exception of reclassification |  |  | $ 3,250,000 |  |

X
- Definition Amount paid due to approval. + References No definition available. + Details
Name: | tovx_AmountToBePaidDueToApproval
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of additional consideration paid on a business combination upon achievement of milestones. + References No definition available. + Details
Name: | tovx_BusinessCombinationContingentConsiderationArrangementsAdditionalAmountPaidOnAchievementOfCertainMilestones
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments to be made after initiating patient dosing in the US and phase 2 clinical trial. + References No definition available. + Details
Name: | tovx_PaymentMadeAfterClinicalTrial
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reclassification related to milestone that was met in the current year. + References No definition available. + Details
Name: | tovx_ReclassificationToAccruedExpenses.
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | tovx_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | tovx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tovx_VCNBiosciencesS.LMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |